

To: The United Nations
760 United Nations Plaza
Manhattan
New York City
10017-6818
United States of America

From: Dr. Wassil Nowicky
74, Flat 6, Summit Court
Triq Andrew Cunnigham
Qawra, Malta
e-mail: dr.nowicky@yahoo.de

Dear Sirs and Madams,

There is no greater grief in a family than a child diagnosed with cancer. All my life I have dedicated myself to working on the anti-cancer drug NSC631570 (Ukrain) - the first and only medical preparation in the world that has a selective effect: in a therapeutic dose it destroys only cancer cells, not healthy ones.

The creation of such a medication was the greatest desire of all scientists in the world. But, unfortunately, so far all their attempts have been unsuccessful. Therefore, we can assume that the invention of the NSC631570 is an epoch-making discovery.

Here are the most impressive results of treatment of cancer patients with NSC631570:

1. Patients Daniel Broschart from Germany, who suffers from a disease called "xeroderma pigmentosum". This patient had to undergo 54 operations before he reached the age of 16 (<http://www.ukrin.com/docs/daniel-b-english.pdf>). Today Daniel is 31 years old and he is able to work normally. Daniel is the first and only patient in the world with xeroderma pigmentosum to live that long. People with this diagnosis live only up to 16 years.



Daniel mit 3 Jahren
Auch hier ist die Hyperpigmentierung zu erkennen



Daniel mit 6 Jahren
Multiple Hauttumore sind zu erkennen




Daniel nach einem großen Transplantationseingriff



Daniel, Januar 2012

2. 3-year-old Stefan Dan from Austria with a diagnosis “generalized lymphangiomatosis” was sent home by doctors to die in 1995 after all possible treatments offered by traditional medicine had been used (<http://www.ukrin.com/en/obstructive-tactics-consequences>). Stefan is 24 years old now. He is intelligent, can read, write and draw and even plays the piano, but, unfortunately, he remained crippled for all his life due to an incomprehensible and illegal ban on his treatment with the preparation NSC631570.



3. Patient S.S. with a diagnosis of xeroderma pigmentosum (<https://ukrin.com/en/xeroderma>).



Patient S.S. before the therapy with Ukrain. Deforming invasive malignant melanoma of the nose. April 2004.



Autofluorescence of NSC-631570 at the melanoma area under UV-light during the first intravenous injection. May 2004.



Patient S.S. in December 2004. Complete regression of the tumor, with connective tissue substitution.

These cases of cure are unique, because no drug in the world would have given such impressive results.

When I noticed that NSC631570 is extremely effective in the treatment of cancer in children, and based on the results of clinical trials, where NSC631570 caused complete remission in 64% of hopelessly cancer children, while in adults under the same conditions only 10%, on the 24 of March 2011 I asked the Austrian Minister of Health to provide this drug, which has no side effects, free of charge for 11 children who are sent home as hopelessly ill (<http://www.ukrin.com/de/taxonomy/term/19>).

What should be noted it is the fact that the efficacy, safety and quality of this preparation were proved primarily in Austria by the Seibersdorf Research Center.

In response on that, on the 11 of November 2011, AGES (Austrian Agency for Health and Food Safety) officials illegally confiscated 5,644 ampoules of the NSC631570 from the Nowicky Pharma office in Vienna and banned the manufacturer DYCKERHOFF Pharma GmbH & Co" (Germany) to send the already ready produced ampoules to patients, justifying this action as follows:

"... the preparation "Ukrain" has lost its registration in Ukraine the day before" (<http://ukrin.com/docs/2011-11-11-ages-niederschrift.pdf>), which was and is not true. As of November 11, 2011, NSC631570 was officially registered in Ukraine.

The following week, on November 14, 2011, by the order of the Minister of Health of Ukraine, the registration certificate UA/9110/01/01 (on NSC631570) was temporarily suspended. Such facts suggest that there is a corruption component here.

And then they started harassing me and my family. There were enough unfounded allegations by two Austrian Ministry of Health officials that NSC631570 had no effect, and I was imprisoned on September 4, 2012, and my company Nowicky Pharma was called a "criminal group." This was in violation of international law, ethics and neglect of human rights. According to the existing legal practice, they were obliged to ask for explanations from me or to seek a competent assistance from medical experts, whether this statement is really justified

(Annex 16 — <http://www.ukrin.com/docs/Beschwerde-gegen -Anordnung.pdf>; Annex 17 — <http://ukrin.com/docs/Habicher 12 09 2014.pdf>; Annex 18 — <http://ukrin.com/docs/Unterkofler 12 09 2014.pdf>). My lawyers filed dozens of complaints about procedural violations, but they remained without any answer.

On that day, September 4, 2012, about 60 employees of the Austrian Ministry of the Home Affairs and AGES broke into the Nowicky Pharma office in Vienna. They took the keys to all the apartments, which gave them access to all the premises. Not only the office and laboratory where I conducted research, but also all my family's private homes were opened, and everyone was given the opportunity to go everywhere and take things without the presence of any of the trustees, as required by Austrian law, and without an appropriate report. Computers, materials for the future scientific publications, and all new research products were removed from the office. 268,000 ampoules of NSC631570 were confiscated. And although on the 11 of December 2012 the District Criminal Court of Vienna issued the following decision: *"The warrant application should have been rejected due to a lack of justification on the part of the Vienna Public Prosecutor's Office"* (Annex 19 — <http://ukrin.com/docs/Beschluss%2011.Dez .2012 1.pdf>), so far they have not been returned.

My children were also taken to the police station, where they were held from 9 a.m. to 11 p.m., and were allegedly intimidated by 10 years in prison if they would not answer questions and claiming that their relatives were criminals. In addition, they said that they were not even allowed to drink water.

I was kept in prison for 6 weeks. When I was imprisoned, I told to the official that when I would be released, I would protest the actions of Austrian officials. To which I was told: "You will not get out of here, and you will be taken out of here in a horizontal position. You will be rehabilitated posthumously, and the family will be apologized for". While in prison, I could not call anyone, no one had the right to visit me. Professors from Germany sought my release for 2 weeks (recording of the press conference in Vienna on January 25, 2013: <http://www.youtube.com/watch?v=PpiVJla5sEs>, <http://www.youtube.com/watch?v=FNrD8B9diGI>, <http://www.youtube.com/watch?V=aYM8Rdk9-KQ>).

When the accusation of ineffectiveness of the preparation NSC631570 was dropped, criminal proceedings were instituted against me for the re-labeling ampoules of NSC631570.

Carrying out my research, I noticed that cancer patients change the smell and color of urine after taking the drug NSC631570. This suggests that certain substances in NSC631570 react biochemically with certain substances in cancer cells, resulting in the plausibility of a new biochemical compound that changes the color and odor of urine. I used this factor to work on an early diagnosis of cancer.

It is known that alkaloid salts do not lose their efficacy over years. And the NSC631570 actually consists of the ions of alkaloid salts. After 11.11.2011 all the ampoules have been confiscated and the manufacturer DYCKERHOFF Pharma GmbH & Co KG (Germany) was forbidden to send new already manufactured ampoules to patients I decided not to interrupt the treatment of cancer patients who lived thanks to it and re-labeled ampoules with NSC631570, which expired. And gave them to cancer patients. This step can be justified by §10 of the Austrian Criminal Code (https://www.jusline.at/10_Entschuldigender_Notstand_StGB.html).

The fact that the drug has not lost its effect was confirmed by the results of tests AGES Gutachten IAM (Appendix 22 - Results of test of Ukrain. AGES: Gutachten IAM, 13.12.2011), the results of tests Seibersdorf laboratory (Appendix 23 - Results of test of Ukrain. Seibersdorf Laboratories, 24.02.2015) and expert opinion Dr. Dobianer, appointed by the court (Das Expertengutachten), 15HV6 / 13d wegen §146ffStGB (Appendix 24 - Results of the test of Ukrain. Mag. Dr. Karl Dobianer, MAS, 18.03.2016).

The re-labeling of medical preparations is practiced by many companies, e.g. such as Roche. According to Roche spokesman Nicolas Dunant, *"In general, it is quite normal that after receiving positive results of a drug test, its validity can be extended"* (<http://ukrin.com/de/node/373>).

Now I am free, but I am constantly under psychological pressure. I can't go home to Vienna, and I have to stay in the UAE or other European countries, I have no way to do scientific work, because I have not been returned all the illegally seized ampoules of the drug NSC631570 and research products yet.

The scientific world has highly appreciated my work. I was nominated for the Nobel Prize in 2004 and in 2007 for the Alternative Nobel Prize "The Right Livelihood Award" (Annex 1 - <http://www.ukrin.com/en/nobel-prize>). If this award would have been given to me, you can imagine how many people would learn about NSC631570! But it seems that more important is not what has been done, but who did it. As it happened with Professor Oleg Gornikevich, who discovered dopamine (Annex 2 - <http://ukrin.com/en/nobel-Prize-prestige>).

Prevention of the registration of NSC631570 in Austria as a country of origin since 28.07.1976 makes it difficult to register it in other countries, which makes the drug inaccessible to all cancer patients. According to the then law "Spezialitätenordnung" BGBl Nr. 99/1947, if a new drug was manufactured on the basis of the already registered substances, and its therapeutic advantage over the original drug was proven, it had to be registered immediately. In this case, neither preclinical nor clinical studies were required. That is, in 1976 ALL CONDITIONS FOR REGISTRATION WERE FULFILLED.

And on the basis of the so-called "pipeline principles", the application for registration NSC631570, even today, must be considered in accordance with the Law "Spezialitätenordnung" BGBl Nr. 99/1947, which was in force at the time of application (Annex 5 – <http://www.ukrin.com/docs/Brief an DrHauer.pdf>).

By 1992, the Austrian Ministry of Health had been provided with more than 400 histories of cancer patients who had exhausted all treatment options, who had been sent home as hopelessly ill, and who had been treated with NSC631570: in some of those patients it had improved and prolonged life, in the second part it caused the partial remission, and in the other - complete remission, which lasted more than 10 years.

In 1992, the Austrian Ministry of Health recognized the efficacy of the drug, describing the tolerability of NSC631570 as "excellent" and "no side effects" in its final report GZ 21.405 / 1011-II / 1/8/92. Therefore, the Ministry knew the price of this drug concluding remarks on para 34 AMG (August 1992), GZ 21.405 / 1011-II / 1/8/92, des Arzneimittelberates gez. Prof. Dr. G. Hitzemberger und sektionschef Dr. G. Liebeswar (Annex 6 - www.ukrin.com/docs/Zitate_Abschlussgutachten_1992.pdf).

Surprisingly, NSC631570 was not registered. Instead, in 1993, the Austrian Ministry of Health submitted an additional requirement for comparative clinical trials according to the protocol approved by the Austrian Ministry of Health (Annex 7 - http://www.ukrin.com/docs/Arrouas_1993.pdf).

Such studies were conducted and published in the professional literature in 1996. The results of the study: the survival rate (21 months) in the group diagnosed with colorectal cancer who used NSC631570 (48 patients) was 78.6%, and in the group who received chemotherapy (48 patients) - 33.3% (Annex 8 - http://www.ukrin.com/docs/Susak_1996.pdf - pp. 43, 45).

In addition, all physicians who worked with NSC631570 under the approved protocol under section 42 of the AMG (Law on Medicinal Products) reported extremely positive results of their treatment and requested the registration of this medicinal product in Austria as soon as possible (Annex 9 - <https://ukrin.com/docs/erfahrungsberichte.pdf>).

Despite this, to date, the Austrian government - the country of origin NSC631570 - does not provide the registration for this drug. Thus makes it inaccessible to all cancer patients, especially children, which is, in our opinion, a violation of Art. 7 of the Rome Statute "crimes against humanity", namely: *"deliberate creation of living conditions, in particular deprivation of access to ... medicines"*.

At the same time, as we can learn from Dr. Eleanor Thun-Hohenstein's book "Cancer Treatment is Undesirable" the Austrian government grants registration to the highly toxic drug "TAXOL" of the American company "Bristol Myers", which was registered only 5 months after the application for registration and on the basis of its use only in 17 patients (<http://www.ukrin.com/files/book.pdf> - p.30). This fact and the fact of non-registration of NSC631570, the country of origin of which is Austria, is a violation of §7 of the Austrian Constitution, which guarantees all the citizens

equal rights.

Delays in registration have been going on for decades and it is unknown how long it may last and cancer patients cannot wait. Every year in Austria alone, about 200 children die on cancer. During this time more than 6,000 children's lives could have been saved (Annex 12 - <http://www.ukrin.com/en/obstructive-tactics-consequences>).

Austria has a population of about 8 million people. About 39,000 people get cancer each year, 20,000 of whom die each year. Of these, about 5,000 suffer from rectal and colon cancer, including about 3,000 deaths a year.

If NSC631570 had been registered, more than 1 million lives could have been saved in the absence of registration (as 75% is the survival rate of NSC631570). Ignoring this information is a deliberate crime of Austrian officials against their own citizens.

According to the famous Dr. Burghardt Ashhoff from Germany, among the 5,000 cancer patients who have exhausted all treatment options and were sent home as terminally ill, 20% of those treated with NSC631570 still live quietly today. While the survival rate among patients treated with chemotherapy as first-line therapy is only 2.1% (Annex 15 - Protocol: DI. Dr. Wassil NOWICKY ua wegen: §§ 146 ua StGB, 29.04.2015 - Article 37).

According to the World Health Organization, 10-12 million people are diagnosed with cancer each year, and about 8 million die. Experts believe that if an effective prevention is not developed in the next 15-20 years, the number of cancer patients will increase to 21,4 million people in 2030, and deaths - up to 12 million.

In 2016, the Austrian magazine Profil (# 25. 47. Jg. 20 June 2016) published an article informing that the Austrian government had allocated 200 million Euros for the development of anticancer proton therapy (Pp. 66-67).

New initiatives and developments are supported around the world, but this does not give the right to make the existing, the world's first ionic drug inaccessible to cancer patients. I became a founder in the development of anticancer proton therapy. It is known that cells have a negative potential, and cancer - even more negative, so I used this one factor and developed the alkaloid of celandine with a positive potential, due to which it accumulates in

cancer tumors and causes their remission. That is its uniqueness and positive effect.

Failure to register NSC631570 in Austria as the country of origin is a deliberate disqualification of the drug, which has a selective effect.

I ask you to pay attention to the above mentioned facts, because I see it as a deliberate crime not so much against me and my family and the company "Nowicky Pharma", but against people with cancer around the world, especially children with cancer, who are deliberately doomed to pay for terrible illness not only by life, but also by terrible torments from chemotherapy.

One can imagine how dangerous a chemotherapy procedure is if doctors have to carefully protect themselves with goggles, a mask and respirators, and rubber gloves to avoid contact with a carcinogen. Chemotherapy has very strong side effects, is carcinogenic, which itself programs the occurrence of cancer, and in a very small percentage can help.

Without registering NSC631570, patients are deliberately deprived of the opportunity to choose treatment with a drug that in therapeutic dose has no side effects and is neither carcinogenic nor mutagenic, the anti-cancer effect of which is proven by a number of scientific studies reflected in professional publications, more than 190 of which are in PubMed (<http://www.ncbi.nlm.nih.gov/pubmed/?term=ukrain>).

Sincerely and with best regards,

Dr. Wassil Nowicky

14.11.2020

List of applications:

- 1 — History of Nobel Prize Nomination. Letter of Professor, PhD, M.D., D.hx. id I. Nefyodov — <http://www.ukrin.com/en/nobel-prize>
- 2 — Dr. Wassil Nowicky. Is the Nobel Prize Losing its Prestige? — <http://ukrin.com/en/nobel-Prize-prestige>
- 3 — Semmelweis effect. From Wikipedia, the free encyclopedia — https://en.wikipedia.org/wiki/Semmelweis_reflex
- 4 — CHRONOLOGIE DER GESCHICHTE DES KREBSMITTELS UKRAIN — <http://www.ukrin.com/docs/chronologie.pdf>
- 5 — E-letter to Dr.Christian Hauer and his answer of 05.09.2011 — http://www.ukrin.com/docs/Brief_an_DrHauer.pdf
- 6 — The final report on NSC 631570 of the Austrian Ministry of Health (August 1992): GZ 21.405/1011 – II/1/8/92 — https://ukrin.com/docs/Zitate_Abschlussgutachten_1992.pdf
- 7 — GZ. 21.405/530-II/A/8/93, Stellungnahme zu Prüfprotokollen Ukrain, Gutachten Nr.558 — http://www.ukrin.com/docs/Arrouas_1993.pdf
- 8 — Results of clinical studies. Comparison of chemotherapy and X-ray therapy with Ukraine mono therapy for colorectal cancer — http://www.ukrin.com/docs/Susak_1996.pdf
- 9 — Erfahrungsberichte von Ärzten, Wissenschaftlern und Patienten über Ukrain — <http://www.ukrin.com/docs/erfahrungsberichte.pdf>
- 10 — Fachinformation TAXOL — http://ukrin.com/docs/Taxol_de_93.pdf
- 11 — The clinical efficacy of adjuvant systemic chemotherapy with gemcitabine and NSC-631570 in advanced pancreatic cancer. Pancreas - MO6367 — <http://www.ukrin.com/beilagen/beilage9.pdf>
- 13 — Korrespondenz mit Bundesministerium für Gesundheit. Brief an Bundesminister für Gesundheit, 24.03.2011 — <https://ukrin.com/index.php?q=de/taxonomy/term/19>
- 14 — Niederschrift: 670.015-17-11-INS, Wien, 11.11.2011 — <https://ukrin.com/docs/2011-11-11-ages-niederschrift.pdf>
- 15 — Protokoll: DI. Dr. Wassil NOWICKY u.a. wegen: §§ 146 u.a. StGB, 29.04.2015
- 16 — BESCHWERDE gegen die Anordnung der Beschlagnahme von 166 Stück UKRAIN-Ampullen. 15 Hv 6/13d, Wien, 13.08.2014 — <http://www.ukrin.com/docs/Beschwerde-gegen-Anordnung.pdf>
- 17 — Aufsichtsbeschwerde, Wien, 12.09.2014 — https://ukrin.com/docs/Habicher_12_09_2014.pdf
- 18 — Strafanzeige an die Staatsanwaltschaft, Wien, 12.09.2014 — https://ukrin.com/docs/Unterkofler_12_09_2014.pdf

- 19 — Beschluss 317 HR 235/12 d, Wien, 11.12.2012 — <https://ukrin.com/docs/Beschluss%2011.Dez.2012.1.pdf>
- 20 — BENACHRICHTIGUNG der Verteidigerin/des Verteidigers von der Einstellung des Verfahrens, Zentrale Staatsanwaltschaft zur Verfolgung von Wirtschaftsstrafsachen und Korruption (WKStA), 020 8 St 62/13m - 1, 20.09.2013 — http://ukrin.com/docs/Nowicky_Einstellung_20_09_13.pdf
- 21 — Proof of payment taxes from Kanzlei Dr. Staribacher & Dr. Obermay- er. 19.11.2013 — <http://www.ukrin.com/docs/Finanzaufwand.pdf>
- 22 — Results of test of Ukrain. AGES: Gutachten IAM, 13.12.2011.
- 23 — Results of test of Ukrain. Seibersdorf Laboratories, 24.02.2015.
- 24 — Results of test of Ukrain. Mag. Dr. Karl Dobianer, MAS, 18.03.2016.
- 25 — Haltbarkeit von Tamiflu Roche überklebt Verfall-Datum von Grippemittel. Roche überklebt Verfall-Datum von Grippemittel — <http://ukrin.com/de/node/373>